News und Analysen
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
On Nov. 28, the Food and Drug Administration (FDA) announced that it was opening an investigation into the possibility of previously unknown serious safety risks associated with the hottest and most
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge
Is Now the Right Time to Buy AstraZeneca Stock?
With shares of AstraZeneca (NASDAQ: AZN) returning 55% over the last three years, easily topping the market's return of 29%, it's no surprise why investors might be curious about whether there's
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days.
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the
3 Dividend Stocks Trading at 52-Week Lows
I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap.
In today's video I will look at three
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
While some stocks may not be attracting quite the same hype they were a few years ago, that doesn't mean the quality of their underlying businesses has evaporated. If your intention is to own great
Is Pfizer Stock a Buy Now?
Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. The top drugmaker can't seem to catch a break. Revenue from its COVID-19 products is down big, and
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
Sarepta Therapeutics (NASDAQ: SRPT) is a mid-cap stock that has the potential to be a big player in the gene therapy market -- at least, so the business and its investors hope. It has made for a
3 Dividend Stocks You Can Safely Hold for Decades
Remember Montgomery Ward, Lehman Brothers, and Pan Am? They were all well-known publicly traded companies that paid dividends. And they all went out of business.
Investors who bought those stocks
Better Dividend Stock: AbbVie vs. Medical Properties Trust
Income-seeking investors have some interesting options to choose from in the healthcare sector right now. AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not
2 Healthcare Stocks to Buy Hand Over Fist in December
As the year draws to a close, it's as good a time as any to review one's investments and consider adding more money into the stock market. The goal shouldn't be to take advantage of the January
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
As reported by Fierce Biotech on Nov. 22, gene-therapy star CRISPR Therapeutics (NASDAQ: CRSP) laid off 10% of its employees shortly after reporting its Q3 earnings earlier in the month. Given that
3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows
Are you looking for some quality dividend stocks to buy right now? When it comes to investing, it's often a good idea to check out those that haven't been doing too well lately and are trading near
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
These days, it seems like biotech buyout offers are falling from the sky. During the week ended Dec. 6, AbbVie (NYSE: ABBV) announced not one but two big acquisitions.
The pharma giant's latest big
My Take: 4 Strong Growth Stocks to Buy This Week
Are you looking for new growth stocks for your portfolio? The idea was compelling a week ago when the market was roaring higher. Now, with fresh headwinds blowing, not so much.
Just bear in mind
Got $5,000? These 3 Stocks Are Deep-Value Buys Right Now
A $5,000 investment may not seem a significant amount to some, but it can generate tremendous returns in the long run. If you were to invest in the S&P 500, which averages an annual return of around
Is AbbVie Stock a Buy Now?
Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. That's because it will need to become less reliant on Humira, its blockbuster
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?
Many investors have flocked to big pharma stocks throughout the years. And doing so has paid off handsomely with several of those stocks.
AbbVie (NYSE: ABBV) and Eli Lilly (NYSE: LLY) stand out as
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
In the gene editing therapies space, there aren't any competitors being watched more closely than Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP). The pair scored
Humana Announces $500K Investment in the Virginia Health Care Foundation to Boost Behavioral Health Workforce Development and Support
Leading health and well-being company Humana today announced a meaningful investment of $500,000 in the Virginia Health Care Foundation (VHCF). This funding will bolster crucial behavioral health
Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now